Archer Materials
Technology

ASX Announcement (ASX: **AXE**) 19 November 2026

Archer completes beta prototype of Biosensor; progressing towards clinical trials

Highlights

- Archer has advanced the engineering and development of its Biosensor beta prototype
- The Beta prototype translates positive alpha results into an integrated, point of care testing kit.
- Beta prototype is ready for external testing and validation ahead of clinical trials and for first stages of manufacturing development by specialist medical device contract manufacturers.
- Discussions progressing with tier-one clinical partners to support external validation.

Archer Materials Limited (ASX: AXE), a quantum company developing computing, sensing, and medical diagnostic technologies, has completed the development of its Biosensor beta prototype, marking a key engineering milestone in its point-of-care blood-testing technology.

Following positive testing and results from the biosensor platform's alpha prototype[1], the Company's engineering team has completed the work required to bring the cartridge, chip packaging, sensors, reader, and readout electronics together into an integrated, point of care testing kit. The beta prototype supports the complete testing workflow, from blood sample application through to analysis and a displayed result; in just six minutes from fingerpick sample to result.

Completion of the beta prototype moves the program from internal engineering development towards external testing, validation and clinical trials. The integrated beta prototype is designed to be operated as an end-to-end kit by external users, allowing the Company to evaluate performance, sample handling, clinical workflows, and usability in external settings. External testing is a critical milestone in the development of a medical diagnostic device, providing independent evidence of how accurately, reliably, and easily the Biosensor performs in real-world clinical settings. The results will help guide final product development and provide essential evidence to support future clinical trials, regulatory approval, and commercialisation.



Archer's Biosensor beta prototype reader and blood-testing cartridge.

Additionally, the beta prototype is now ready for external testing and studies; as well as initial manufacturing design with specialist contract manufacturers. Archer is progressing discussions with tier-one clinical partners in Australia and internationally to conduct external validation, including evaluation of its lithium testing application against established laboratory methods. These activities represent key steps towards commercialising lithium testing as the Biosensor platform's beachhead application, while laying the foundation for a broader pipeline of diagnostic applications, including blood potassium testing. Clinical customer feedback has driven the choice of lithium as the initial application for the technology.

Archer Materials CEO Dr Simon Ruffell said: *"Archer's Biosensor is now a highly sophisticated integrated medical device bringing several complex workflows into a single rapid, easy-to-use point-of-care device, to help ensure more effective and simple care for patients. I am proud of the incredible work our engineering and development team have completed to bring us to the point where we can put the Biosensor technology platform into users' hands for testing.*

"The next phase is about building evidence: understanding how the device performs in practical settings and using feedback from both commercial manufacturing and clinical partners to guide its final phase of development."

1. ASX Announcement *Archer develops early Biochip prototype*, 30 January 2026, *https://asx.api.cmfyapp.com/asx-research/1.0/file/2924-03050833-2A1650534&v*

The Board of Archer authorised this announcement to be given to ASX.

Investor and media enquiries

Stef Winwood
investors@archermaterials.com
+61 433 307 853

About Archer

Archer is a quantum technology company that operates within the semiconductor industry. The Company is developing advanced semiconductor devices, including chips relevant to quantum computing, sensing, and medical diagnostics. Archer utilises its global partnerships to develop these technologies for potential deployment and use across multiple industries. www.archerx.com.au